Randomized Double-Blind Placebo-Controlled Phase 2 Study Of Bemarituzumab Combined With Modified Folfox6 (Mfolfox6) In First-Line (1l) Treatment Of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (Fight).

Zev A. Wainberg,Peter C. Enzinger,Yoon-Koo Kang,Kensei Yamaguchi,Shukui Qin,Keun-Wook Lee,Sang Cheul Oh,Jin Li,Haci Mehmet Turk,Alexandra Carolina Teixeira,Giovanni Gerardo Cardellino,Raquel Guardeño,Siddhartha Mitra,Yingsi Yang,Helen Collins,Daniel V.T. Catenacci

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 71|浏览14

暂无评分

摘要

160Background: Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to FGFR2b, inhibits ligand binding and mediates antibody-dependent cell-mediated cytotoxi...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要